Table 2.
Univariable analysis on survival outcomes of absolute cell counts and immune-inflammatory indices baseline and early Δ, and baseline clinical parameters.
| Inflammatory indices | ROC-based cut-off values | PFS | OS | ||
|---|---|---|---|---|---|
| mPFS(95% CI) | Univariable(HR; 95% CI; p value) | mOS(95% CI) | Univariable(HR; 95% CI; p value | ||
| Absolute cell counts | |||||
| Baseline Neutrophils (x10e3/L) |
≥ 4330 | 6.9 (5.1-10.9) |
1.25; 0.99-1.56; p = 0.059 | 19.4 (12.6-26.4) |
1.87; 1.40-2.49; p < 0.001 |
| < 4330 | 10.2 (8.4-14.3) |
1.00 (ref) | NR | 1.00 (ref) | |
| Early Δ Neutrophils | ≥ 730 | 6.1 (4.7-9.2) |
1.29; 1.02-1.62; p = 0.033 | 20.8 (17.4-43.9) |
1.34; 1.01-1.80; p = 0.046 |
| < 730 | 11.0 (9.3-13.9) |
1.00 (ref) | 46.9 (25.7-NR) |
1.00 (ref) | |
| Baseline Lymphocytes (x10e3/L) |
< 1460 | 6.4 (5.0-8.4) |
1.57; 1.25-1.98; p < 0.001 | 20.0 (17.1-27.7) |
1.88; 1.39-2.53; p < 0.001 |
| ≥ 1460 | 13.9 (9.9-18.5) |
1.00 (ref) | NR | 1.00 (ref) | |
| Early Δ Lymphocytes | ≥ -10 | 8.4 (5.5-12.1) |
1.10; 0.88-1.38; p = 0.41 | 25.7 (20.1-43.9) |
1.15; 0.86-1.54; p = 0.34 |
| < -10 | 9.9 (8.1-12.5) |
1.00 (ref) | 46.9 (23.0-NR) |
1.00 (ref) | |
| Baseline Platelets (x10e9/L) |
≥ 263 | 8.4 (5.1-10.1) |
1.40; 1.11-1.76; p = 0.004 | 19.4 (13.8-25.7) |
1.92; 1.44-2.56; p < 0.001 |
| < 263 | 10.9 (7.8-15.0) |
1.00 (ref) | NR | 1.00 (ref) | |
| Early Δ Platelets | ≥ 17 | 8.5 (5.5-10.5) |
1.07; 0.85-1.34; p = 0.56 | 26.4 (20.2-NR) |
0.97; 0.73-1.30; p = 0.86 |
| < 17 | 10.8 (8.0-14.3) |
1.00 (ref) | 34.3 (20.8-NR) |
1.00 (ref) | |
| Indices | |||||
| Baseline NLR | ≥ 3.2 | 5.8 (4.6-8.3) |
1.58; 1.26-1.99; p < 0.001 | 18.7 (11.3-22.7) |
2.10; 1.57-2.80; p < 0.001 |
| < 3.2 | 11.2 (9.5-16.6) |
1.00 (ref) | NR | 1.00 (ref) | |
| Early Δ NLR | ≥ 0.5 | 6.4 (5.0-9.3) |
1.37; 1.09-1.72; p = 0.007 | 21.7 (18.4-43.9) |
1.32; 0.99-1.76; p = 0.062 |
| < 0.5 | 12.1 (9.5-16.8) |
1.00 (ref) | 46.9 (25.7-NR) |
1.00 (ref) | |
| Baseline SII | ≥ 720 | 6.1 (4.7-9.4) |
1.51; 1.21-1.90; p < 0.001 | 18.7 (13.8-22.0) |
2.27; 1.69-3.04; p < 0.001 |
| < 720 | 11.3 (9.5-18.3) |
1.00 (ref) | NR | 1.00 (ref) | |
| Early Δ SII | ≥ 218 | 6.4 (4.6-9.5) |
1.24; 0.99-1.57; p = 0.061 | 24.5 (18.7-NR) |
1.22; 0.91-1.64; p = 0.18 |
| < 218 | 11.0 (9.2-14.7) |
1.00 (ref) | 30.7 (23.7-NR) |
1.00 (ref) | |
| Baseline PLR | ≥ 176 | 6.5 (4.7-9.5) |
1.52; 1.21-1.91; p < 0.001 | 19.9 (15.5-22.7) |
2.23; 1.66-3.01; p < 0.001 |
| < 176 | 11.5 (9.3-16.8) |
1.00 (ref) | NR | 1.00 (ref) | |
| Early Δ PLR | ≥ 21 | 9.2 (5.9-11.3) |
1.07; 0.85-1.35; p = 0.54 | 27.7 (19.4-NR) |
1.09; 0.82-1.45; p = 0.57 |
| < 21 | 9.9 (6.9-14.3) |
1.00 (ref) | 30.1 (21.7-NR) |
1.00 (ref) | |
| Baseline clinical parameter | |||||
| Heng score | Favorable | 22.5 (16.4-35.2) |
1.00 (ref) | NR | 1.00 (ref) |
| Intermediate | 8.2 (5.9-9.5) |
1.85; 1.36-2.51; p < 0.001 | 25.7 (20.1-34.3) |
2.83; 1.79-4.50; p < 0.001 | |
| Poor | 2.9 (2.2-5.5) |
3.28; 2.16-4.99; p < 0.001 | 8.1 (3.7-10.7) |
7.13; 4.12-12.37; p < 0.001 | |
| Metastatic at diagnosis | Yes | 6.4 (5.3-9.3) |
1.21; 0.96-1.53; p = 0.11 | 21.7 (17.5-34.3) |
1.40; 1.05-1.87; p = 0.023 |
| No | 11.2 (9.3-14.7) |
1.00 (ref) | 46.9 (24.8-NR) |
1.00 (ref) | |
| Nephrectomy | Yes | 9.9 (8.3-12.5) |
0.60; 0.42-0.85; p = 0.004 | 43.9 (25.7-NR) |
0.43; 0.29-0.62; p < 0.001 |
| No | 4.0 (2.9-8.8) |
1.00 (ref) | 14.5 (8.6-19.4) |
1.00 (ref) | |
| Histologic subtype | Clear-cell | 9.5 (7.9-11.5) |
0.95; 0.69-1.31; p = 0.77 | 29.5 (22.0-NR) |
1.08; 0.71-1.63; p = 0.72 |
| Non-clear cell | 6.6 (5.0-13.6) |
1.00 (ref) | NR | 1.00 (ref) | |
| Lymph node metastases | Yes | 7.4 (5.6-10.1) |
1.15; 0.92-1.45; p = 0.22 | 25.7 (19.9-30.7) |
1.28; 0.95-1.71; p = 0.10 |
| No | 11.0 (8.8-13.8) |
1.00 (ref) | 46.9 (22.7-NR) |
1.00 (ref) | |
| Viscera metastases | Yes | 9.3 (6.9-11.1) |
1.09; 0.72-1.64; p = 0.69 | 29.8 (22.0-NR) |
1.04; 0.62-1.74; p = 0.88 |
| No | 11.3 (5.8-23.4) |
1.00 (ref) | 25.7 (16.7-NR) |
1.00 (ref) | |
| Bone metastases | Yes | 6.4 (4.6-8.4) |
1.51; 1.20-1.91; p = 0.001 | 18.7 (13.1-25.0) |
1.81; 1.36-2.42; p < 0.001 |
| No | 11.3 (9.3-16.0) |
1.00 (ref) | 46.9 (29.8-NR) |
1.00 (ref) | |
| Line of therapy | 2 | 9.5 (6.6-12.1) |
1.00 (ref) | 30.1 (21.4-NR) |
1.00 (ref) |
| 3 | 9.5 (6.1-13.1) |
1.06; 0.84-1.35; p = 0.61 | NR | 0.97; 0.71-1.31; p = 0.83 | |
| >4 | 8.3 (3.2-16.6) |
0.94; 0.68-1.28; p = 0.68 | 18.1 (9.3-NR) |
0.86; 0.57-1.30; p = 0.48 | |
Early Δ value variations between second and first therapy infusion, mOS median overall survival, mPFS median progression-free survival, NLR neutrophils-to-lymphocytes ratio, NR not reached, PLR platelets-to-lymphocytes ratio, ROC receiving operating curve, SII systemic immune-inflammatory index.
In bold, significant p-values.